Pay in 4 interest-free payments of $6.03 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Mechanism of Action Semaglutide works by binding to GLP-1 receptors in the body
This is an Insight article, written by a selected contributor as part of IAM's co-published content
While the study opens up dialogue about the possible safety of GLP-1 medications during breastfeeding, it's crucial for women to consult with healthcare providers
With the obesity epidemic contributing to rising rates of diabetes, heart disease and other chronic conditions, GLP-1 therapies represent a potential turning point in the fight against these diseases
In clinical trials of Tirzepatide, a dual-acting GLP-1 and GIP agonist currently prescribed for Type 2 diabetes, obese patients lost 21 percent body mass in 1.4 years, surpassing the 15 percent reduction seen with Semaglutide
doi: 10.1016/s1074-7613(00)80606-8 153 ShogomoriHHammondATOstermeyer-FayAGBarrDJFeigensonGWLondonEet al
